8th International China Pharmaceutical R&D Summit,
20-23 May, 2013, Shanghai, China
This meeting was a great opportunity to evaluate the current Chinese R&D innovation ecosystem .
Making China an “Innovation –Oriented Society” by 2020 is a clear target of
the 12th five year plan:
In China the number of scientist is increasing by 8% every year with 49.000 new Ph.D per year and the number of postdoctoral returnees is also increasing by 30%.
The 12th five-year plan has identified the biomedical sector as one of the seven strategic domains and it will allocate 40 billion RMB (4,9 billion Euros) for major new drug development.
China possesses 22 medical high-tech parks with land and tax incentives and the CRO business is still growing at a fast pace.
Insurance coverage is now extended to almost 95% of the population and the government is accelerating the reform of public hospitals and developing a primary care infrastructure across the country.
Nevertheless there are still major challenges to overcome such as:
Integrating all the elements of the value chain in order to become an innovating leader
Transforming the current domestic oriented generic approach to an R&D driven one
Catching-up in coming forward with innovative drugs to address major Chinese medical needs
Investing in long-term and highly risky projects
Improving regulatory bodies transparency on policies and priorities
It may take another 10-15 years until these key issues will be fully addressed in order for China to become a global scientific leader.
Author : Jean-Claude MULLER, Special Advisor,Innovation & International Relationship (I&IR)